ARQT vs the Top Picks average
| Pillar | ARQT | Book avg | Diff |
|---|---|---|---|
| Quality | 0.47 | 0.83 | -0.37 |
| Growth | 1.00 | 0.87 | +0.13 |
| Value | 0.62 | 0.76 | -0.14 |
Averaged across the 30 names in today's Top Picks (mean score 81.6). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
ARQT at a glance
Every figure here comes from the same audited fundamentals behind the score. Charts drawn from data the score does not use say so on the card.
Analyst estimate revisions
| 30-day change | +0.0% |
|---|---|
| 90-day change | -1.9% |
| Forward EPS estimate | $1.30 |
Over the last 90 days, what analysts expect ARQT to earn is drifting lower (-1.9%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A fiscal-year roll fell inside this window: the forward horizon moved on to the next financial year, which shifts the earnings figure without any analyst changing their view. That step is excluded, so the number above covers the rest of the window rather than all of it.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Latest ARQT developments
Recent headlines from across the financial press · updated daily. Links open the source.
- Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable?simplywall.st ·
- Arcutis (NASDAQ: ARQT) insider plans $956K share saleStock Titan ·
- Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18KBenzinga ·
- Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth MomentumChartMill ·
- Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026Kalkine Media ·
- Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQGuruFocus ·
Arcutis Biotherapeutics, Inc. (ARQT): score, valuation & FAQ
Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology company that scores 66.1 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and PEG (A-), while FCF (C-) and P/E (D) rate weaker. On valuation, ARQT sits about 386% above our discounted-cash-flow fair value — the current price implies free-cash-flow growth above 60% a year for the next decade.
Is ARQT a good stock to buy?
Bull Rankings scores ARQT 66.1 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and PEG (A-). A score is a quantitative screen of Arcutis Biotherapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ARQT score 66.1 on Bull Rankings?
The score leans on growth at 99.7 out of 100, with quality the weakest pillar at 46.8 — the three combine geometrically, so a weak one cannot be papered over by a strong one. ARQT earns its highest marks on Rev (A) and PEG (A-), and is held back by FCF (C-) and P/E (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so ARQT is measured against Biotechnology peers, not against the market as a whole.
Is ARQT overvalued or undervalued?
Based on $24.87, ARQT sits about 386% above our discounted-cash-flow fair value — the current price implies free-cash-flow growth above 60% a year for the next decade. It trades at a 113.0x P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ARQT?
The current price of $24.87 implies over 60%/yr free-cash-flow growth sustained for 10 years, according to our reverse DCF model. This aggressive assumption, coupled with a lofty PE of 113, signals that any slowdown in revenue growth or margin compression would trigger a sharp re‑rating; a modest dip to a more realistic growth rate would force the stock toward its 52‑week low of $15.10. Our model's weakest pillar, Quality, scores a mere 47, reflecting concerns around the company's ability to consistently convert its growth into sustainable profitability. Additionally, a debt‑to‑equity of 0.52 leaves limited headroom for financing larger trials, and the high beta of 1.53 amplifies downside in a volatile biotech market. A missed regulatory milestone on the ZORYVE foam would confirm the bear case and crush the valuation.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.